Enanta Pharmaceuticals, Inc. ENTA
7.59 USD -0.39 (-4.89%)
As ofNov 20, 2026, 2:33 PM EST
7.58 Day range 7.79
7.58 52-week range 17.15
- YTD
- -51.87%
- 1 year
- -37.43%
News
benzinga.com JP Morgan Maintains Overweight on Enanta Pharmaceuticals, Lowers Price Target to $17 JP Morgan analyst Anupam Rama maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Overweight and lowers the price target from $19 to $17.
zacks.com Enanta Pharmaceuticals (ENTA) Reports Q4 Loss, Misses Revenue Estimates Enanta Pharmaceuticals (ENTA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.87 per share a year ago.benzinga.com Enanta Pharma Q4 EPS $(0.81) Misses $(0.78) Estimate, Sales $12.868M Miss $14.200M Estimate Enanta Pharma (NASDAQ:ENTA) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.78) by 3.85 percent. This is a 6.9 percent increase over losses of…
businesswire.com Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2026 WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological…benzinga.com Enanta Pharmaceuticals Doses First Patient In Its RESOLVE Phase 2b/3 Clinical Trial Of Zelicapavir In Adults At High Risk Of Severe Outcomes From RSV; Topline Data Expected In 2027 The Phase 2b/3 randomized, double-blind, placebo-controlled, multicenter global trial will evaluate the efficacy and safety of zelicapavir in adult outpatients who test positive for RSV and have had…
